*March 2023*
The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer (NSCLC), according to updated data from a phase 1 trial (NCT03260491). Findings from a phase 1/2 trial (NCT02980341) also showed that the agent induced a response in patients with HER3-expressing metastatic breast cancer.
Results from the phase 1 trial showed that patients with EGFR-mutated NSCLC (n = 102) treated with patritumab deruxtecan experienced an objective response rate (ORR) of 40.2% (95% CI, 30.6%-50.4%), including a complete response (CR) rate of 1.0%, a partial response (PR) rate of 39.2%, a stable disease (SD) rate of 38.2%, and a progressive disease (PD) rate of 12.7%. Notably, 8.8% of patients were not evaluable (NE). The disease control rate (DCR) was 78.4% (95% CI, 69.2%-86.0%). Read more.
